TABLE 2.
Effectiveness of different inhalation therapy options during 6 months follow-up.
| Outcome | Total (N = 695) | LAMA (N = 169) | LAMA/LABA (N = 149) | ICS/LABA (N = 72) | ICS/LABA/LAMA (N = 245) | Others (N = 60) | p-value |
|---|---|---|---|---|---|---|---|
| Δ CAT, Median (IQR) | 2 (8) | 0 (7) | 4 (8.5) | 0 (7.75) | 3 (9) | −0.5 (4) | <0.001 |
| MCID of CAT, n (%) | <0.001 | ||||||
| Yes | 341 (49.1) | 54 (32.0) | 98 (65.8) | 23 (31.9) | 150 (61.2) | 16 (26.7) | |
| No | 354 (50.9) | 115 (68.0) | 51 (34.2) | 49 (68.1) | 95 (38.8) | 44 (73.3) | |
| AE during 6 months follow-up, Median (IQR) | 0 (1) | 1 (2) | 0 (0) | 0 (1.75) | 0 (2) | 0 (2) | <0.001 |
| AE during 6 months follow-up, n (%) | 0.932 | ||||||
| Yes | 154 (22.2) | 37 (21.9) | 31 (20.1) | 14 (19.4) | 58 (23.7) | 14 (23.3) | |
| No | 541 (77.8) | 132 (78.1) | 118 (79.9) | 58 (80.6) | 187 (76.3) | 46 (76.7) | |
| Severe AE during 6 months follow-up, n (%) | 0.011 | ||||||
| Yes | 60 (8.6) | 8 (4.7) | 23 (15.4) | 4 (5.6) | 21 (8.6) | 4 (6.7) | |
| No | 635 (91.4) | 161 (95.3) | 126 (84.6) | 68 (94.4) | 224 (91.4) | 56 (93.3) | |
| Prescription outcome, n (%) | <0.001 | ||||||
| Continuous using | 571 (82.1) | 129 (76.3) | 145 (97.3) | 47 (65.3) | 191 (78.0) | 59 (98.3) | |
| De-escalation therapy | 66 (9.5) | 0 (0) | 3 (2.0) | 9 (12.5) | 54 (22.0) | 0 (0) | |
| Escalation therapy | 6 (0.9)` | 4 (2.4) | 1 (0.7) | 0 (0) | 0 (0) | 1 (1.7) | |
| Augmented | 52 (7.5) | 36 (21.3) | 0 (0) | 16 (22.2) | 0 (0) | 0 (0) |
Note: For comparison, Chi-square or Fisher’s test was used for categorical variables, and Kruskal-Wallis H test were used for continuous variables; the bold p-values indicate statistical significance.
Abbreviations: CAT, COPD assessment test; Δ CAT was calculated by subtracting the baseline CAT score from the follow-up CAT score; MCID, minimum clinically important difference, defined as attaining minimum clinically important differences of CAT (decrease ≥2) assessed at 6 months follow-up; AE, acute exacerbation; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.